Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

June 2011, Clovis Oncology ($CLVS @ClovisOncology) entered into a license agreement with Pfizer ($PFE @Pfizer) to obtain exclusive global rights to develop and commercialize rucaparib. The rights are exclusive even as to Pfizer and include the right to grant sublicenses. Upfront Payment $7.0MM Milestone 1 $0.4MM, April 2014, for the initiation of ARIEL3 pivotal registration study Milestone 2.0 $88.5MM […]

Cibiem (New York, NY), a development-stage medical device company focused on sympathetic nervous system-mediated diseases, closed a $10M Series A financing. Participants include SV Life Sciences and Third Rock Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account […]

Medivo (New York, NY) a commercial-stage healthcare data analytics company focused on organization of patient lab results, closed a $7M Series A financing. Participants include Safeguard Scientifics.

ZocDoc (New York, NY) a commercial-stage web-based healthcare provider network and appointment service, closed a $25M Series C, bringing the total financing to $75M. Participants inculde Goldman Sachs and DST Global.

Phreesia (New York City, NY) a commercial-stage provider of patient check-in systems, closed a $20M Series D financing. Participants include VantagePoint, Ascension Health Ventures, Polaris Venture Partners, HLM Venture Partners, Long River Ventures and BlueCross BlueShield Venture Partners.

Phreesia (New York, NY) a commercial-stage developer of patient intake data, closed a $16M Series D financing. Participants include Ascension Health Ventures, BlueCross BlueShield Venture Partners, Sandbox Industries, Polaris Venture Partners, HLM Venture Partners and Long River Ventures.

Rheonix (Ithaca, NY) a development-stage molecular diagnostic company focused on immunoassays, pathogen identification gene sequence detection and cell-based assays, closed a $12.6M Series A financing. Participants include Cayuga Venture Fund.

Aureon Laboratories (New York, NY) a commercial-stage diagnostic company focused on prognostic assays for prostate cancer and PSA, closed a $7M Series D financing. Participants have included Atlas Venture, New Leaf Venture Partners, Sprout Group and Pfizer.

Intercept Pharmaceuticals (New York, NY) a clinical-stage small molecule drug company focused on modulation of bile acid signaling in primary biliary cirrhosis and type II diabetics with fatty acid liver disease, closed a $25M Series B financing. Participants include Genextra.

Therasis (New York, NY) a development-stage computational systems biology cancer HTS drug discovery platform, closed a $12M Series A financing. Participants include Tilocor Life Science. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Curemark (Rye, NY) a clinical-stage biopharma company focused on the treatment of neurological disease (autism and ADHD), clased a $6.5M Series A financing. Participants were not disclosed.

Paradigm Spine (New York, NY) a clinical-stage medical device company focused on lumbar stabilization and interspinous implants, closed a $6.5M Series E financing. Participants include Praefinium Group and Trevi Health Ventures.

Core Dynamics (Orangeburg, NY) a development-stage company focused on the freezing and lyophilization of white blood cells and stem cells and their preservation and storage at room temperature, closed a $17.9M Series B financing. Participants were not disclosed.

« Previous Entries  Next Page »

to top of page...